

## A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING

Huadong Tang<sup>1</sup> and Michael Mayersohn

*Department of Pharmaceutical Sciences, College of Pharmacy, The University of Arizona, Tucson, Arizona*

Received February 9, 2005; accepted June 2, 2005

### ABSTRACT:

Sixty-one sets of clearance (CL) values in animal species were allometrically scaled for predicting human clearance. Unbound fractions ( $f_u$ ) of drug in plasma in rats and humans were obtained from the literature. A model was developed to predict human CL:  $CL = 33.35 \text{ ml/min} \times (a/Rf_u)^{0.770}$ , where  $Rf_u$  is the  $f_u$  ratio between rats and humans and  $a$  is the coefficient obtained from allometric

scaling. The new model was compared with simple allometric scaling and the "rule of exponents" (ROE). Results indicated that the new model provided better predictability for human values of CL than did ROE. It is especially significant that for the first time the proposed model improves the prediction of CL for drugs illustrating large vertical allometry.

Allometric scaling is widely used in predicting human clearance (CL) based on animal data. Since prediction errors are commonly observed in the practical application of this approach, various modifications to allometric scaling have been proposed. These modifications include in vitro metabolic data (Lave et al., 1997), correction by either maximum life-span potential (MLP) or brain weight (BrW) (Mahmood and Balian, 1996b), the "rule of exponents" (ROE) (Mahmood and Balian, 1996a), and scaling unbound CL (Feng et al., 2000). Correction by in vitro metabolic data was successful in predicting human CL of 10 extensively metabolized drugs (Lave et al., 1997). Based on a data analysis of 16 drugs, however, Mahmood (2002) concluded that the use of in vitro data obtained from liver microsomes to predict hepatic CL in humans did not provide reliable predictions. In addition, in vitro metabolic corrections cannot be applied to compounds eliminated by excretion. Scaling unbound CL across animal species improved the prediction for certain compounds (Feng et al., 2000); however, it failed to predict well for a few compounds with large vertical allometry such as diazepam and valproate. Recently, Mahmood (2000) suggested that unbound CL cannot be predicted any better than total clearance. Corrections either with MLP or BrW have been shown to be inappropriate if they are used indiscriminately, which led to the idea of ROE. This rule provides selection criteria for use of MLP or BrW, based on the values of the exponents obtained from simple allometry (Mahmood and Balian, 1996a). Although ROE has been shown to improve the prediction significantly compared with simple allometry, this method is still not satisfactory in predicting large vertical allometry. More recent studies (Nagilla and Ward, 2004)

found that the corrections using MLP or BrW or the rule of exponents in allometric scaling did not result in significant improvements in predictions of human CL. Furthermore, they proposed that the monkey liver blood flow approach was superior to the rule of exponents. This controversy is currently not resolved (Mahmood, 2005; Nagilla and Ward, 2005).

The coefficients ( $a$ ) of the power function have been considered important in determining the magnitude of CL, because the exponents ( $b$ ) have been shown to be relatively constant, with a typical value close to 0.75 (Boxenbaum, 1982). Based upon analysis of more than 60 drugs, we have observed that the water-octanol partition coefficient ( $\log P$ ) and the ratio of unbound fraction ( $f_u$ ) in plasma between rats and humans ( $Rf_u$ ) may provide simple rules for anticipating the occurrence of large vertical allometry. Based upon these findings, therefore, we attempted to develop a new model for predicting human CL.

### Materials and Methods

A literature search was performed to obtain animal data for allometric scaling of systemic CL (CL used in this article refers to systemic CL) and  $f_u$  ratio in rats and humans. Only data sets including at least three animal species were used for scaling. Coefficients and exponents were obtained by fitting body weight and CL,  $CL \times MLP$ , or  $CL \times BrW$  on a log-log scale according to the allometric equation:  $CL$  or  $CL \times MLP$  or  $CL \times BrW = a \times W^b$ . CL in humans was calculated by using the coefficients and exponents obtained and human body weight reported, or by assuming 70 kg (if weight was not reported in the publication). MLP was calculated by using  $MLP = 10.839 \cdot W^{0.636} \cdot BrW^{-0.225}$  (Boxenbaum, 1982). The rule of exponents was applied as described by Mahmood and Balian (1996a): 1) if the exponent from simple allometry is between 0.55 and 0.70, simple allometry is applied; 2) if the exponent is between 0.70 and 1.0,  $CL \times MLP$  approach is applied; 3) if the exponent is greater than 1.0,  $CL \times BrW$  approach is applied; 4) if the exponent is less than 0.50, simple allometry is applied since none of the approaches could improve the prediction. Predictability was assessed by percentage error (PE), which is  $[(CL_{pred} - CL_{obs})/CL_{obs}] \times 100\%$  for over-prediction and,  $[(CL_{obs} - CL_{pred})/CL_{pred}] \times 100\%$  for under-prediction. A power model is proposed,

This work was presented at the American Association of Pharmaceutical Scientists Annual Meeting, Salt Lake City, Utah, October 26, 2003.

<sup>1</sup> Current address: Bioanalytical Department, Wyeth Research, Pearl River, New York.

Article, publication date, and citation information can be found at <http://dmd.aspetjournals.org>.

doi:10.1124/dmd.105.004143.

**ABBREVIATIONS:** CL, clearance;  $Rf_u$ , ratio of unbound fraction in plasma between rats and humans; MLP, maximum life-span potential; BrW, brain weight; ROE, rule of exponents; PE, percentage error; GV150526A, sodium 4,6-dichloro-3-[(E)-3-(N-phenyl)propenamide]indole-2-carboxylate; PK, pharmacokinetic.

TABLE 1

Comparison of predictability of human clearance obtained from simple allometry, the new model equations, and the rule of exponents

The order of drugs is arranged according to the ascending values of exponent b obtained from simple allometry.

Compounds	References	$Rf_u$	$a$	$b$	$CL_{obs}$	Simple Allometry		Equation 5		ROE	
						$CL_{pred}$	PE	$CL_{pred}$	PE	$CL_{pred}$	PE
			ml/min		ml/min	ml/min		ml/min		ml/min	
Indinavir	Lin et al., 1996	1.15	198.00	0.349	1325	872	-52	1757	33	872	-52
Remoxipride	Widman et al., 1993	2.94	36.50	0.362	119	170	43	232	95	170	43
CI-921	Paxton et al., 1990	9.73	13.74	0.439	188	89	-113	44	-332	89	-112
Ofloxacin	Nakamura et al., 1983; Okazaki et al., 1992; Kawakami et al., 1994	1.04	7.58	0.457	146	53	-178	154	5	53	-175
Dofetilide	Smith et al., 1992	0.98	19.20	0.462	105	136	30	330	214	136	30
Nilvadipine	Terakawa et al., 1987; Tokuma et al., 1987; Naritomi et al., 2001	0.90	32.07	0.514	560	285	-96	522	-7	285	-96
Enprofylline	Tsunekawa et al., 1992	0.46	6.34	0.526	315	59	-426	251	-25	59	-434
Ceftizoxime	Murakawa et al., 1980	0.99	11.24	0.563	126	123	-2	217	72	123	-2
Talsaclidine	Leusch et al., 2000	0.99	29.23	0.564	588	321	-82	452	-30	321	-83
Cefoperazone	Sawada et al., 1984	4.23	6.77	0.577	74	79	6	48	-54	79	7
Bosentan	Lave, et al., 1996a; Ubeaud et al., 1995	1.00	17.19	0.578	140	200	43	298	113	200	43
Antipyrine	Boxenbaum and Fertig, 1984; Chiou and Hsu, 1988	1.00	4.52	0.589	43	55	28	107	148	55	28
Moxifloxacin	Siefert et al., 1999	1.15	19.34	0.589	154	236	53	293	90	236	53
Tamsulosin	van Hoogdalem et al., 1997; Matsushima et al., 1998	20.00	61.00	0.594	48	761	1485	79	64	761	1485
Recainam	Scatina et al., 1990	1.02	2.20	0.601	30	28	-6	60	101	28	-7
Nicardipine	Higuchi et al., 1980; Naritomi et al., 2001	1.46	72.34	0.630	472	944	100	673	43	944	100
Cefmetazole	Murakawa et al., 1980; Komiya et al., 1981	3.73	12.80	0.633	129	188	46	86	-50	188	46
Ketamine	Bjorkman and Redke, 2000	0.93	120.50	0.635	1170	1787	53	1412	21	1787	53
Cefotetan	Komiya et al., 1981; Matsushita et al., 1990	7.78	7.13	0.639	30	108	256	31	4	108	260
Tolcapone	Lave et al., 1996b	1.00	7.23	0.646	118	113	-5	153	30	113	-4
Moxalactam	Sawada et al., 1984; Mahmood, 1999	1.28	4.97	0.651	93	79	-18	95	2	79	-18
Propranolol	Chiou and Hsu, 1988; McNamara et al., 1988	1.15	49.68	0.662	1050	827	-27	606	-73	827	-27
Sildenafil	Walker et al., 1999	1.25	28.95	0.679	420	518	23	375	-12	518	23
Tirilazad	Bombardt et al., 1994	2.17	26.50	0.693	580	503	-15	229	-153	503	-15
Ro 24-6173	Lave et al., 1997	1.30	68.82	0.716	840	1440	71	709	-19	477	-76
Sematilide	Hinderling et al., 1993	0.95	19.67	0.727	313	431	38	344	10	135	-132
Cefazolin	Lee et al., 1980; Sawada et al., 1984	0.56	4.79	0.733	53	108	104	174	229	47	-13
Mofarotene	Lave et al., 1997	1.00	11.50	0.733	770	259	-194	219	-252	84	-817
Diazepam	Laznicek et al., 1982; Mahmood and Balian, 1996a	5.00	37.57	0.737	27	860	3087	159	489	466	1626
Caffeine	Lave et al., 1997; Bonati et al., 1984	0.94	6.36	0.750	137	154	12	145	6	71	-93
Cefpiramide	Murakawa et al., 1980; Ohshima et al., 1991	14.59	4.70	0.755	19	6	553	14	-36	20	5
FCE22101	Efthymiopoulos et al., 1991	0.69	11.18	0.756	494	278	-79	285	-73	128	-286
NS-105	Kumagai et al., 1999; Mukai et al., 1999	1.00	7.90	0.759	141	199	41	164	16	155	10
Felbamate	Adusumalli et al., 1991; Palmer and McTavish, 1993	1.19	1.50	0.766	30	39	30	40	33	21	-43
Midazolam	Lave et al., 1997	1.00	52.30	0.785	798	1465	84	702	-14	290	-175
Dolasetron	Sanwald-Ducray and Dow, 1997	0.90	57.44	0.793	1232	1670	36	818	-51	907	-36
Mibefradil	Lave et al., 1997	2.00	66.88	0.804	532	2032	282	497	-7	642	21
Quinidine	Belpaire et al., 1977; Chiou and Hsu, 1988; Mahmood and Balian, 1996a	1.41	47.51	0.805	330	1452	340	500	52	285	-16
Sumatriptan	Cosson et al., 1997	1.01	31.71	0.808	1333	982	-35	474	-181	319	-318
Troglitazone	Izumi et al., 1996, 1997; Mahmood, 1999	0.98	12.44	0.810	411	383	0	236	-74	178	-131
Theophylline	Gaspari and Bonati, 1990; Lave et al., 1997	0.69	1.89	0.817	51	61	19	72	42	42	-21
Amlodipine	Stopher et al., 1988	3.00	29.00	0.821	490	949	94	191	-156	324	-51
DA-1131	Kim et al., 1998a,b	1.00	11.58	0.825	353	385	9	220	-61	104	-239
Alfentanil	Bjorkman and Redke, 2000	1.23	24.85	0.834	448	859	92	337	-33	253	-77
Norfloxacin	Nakamura et al., 1983; Mahmood and Balian, 1996a	1.02	90.02	0.836	1360	3139	131	1050	-29	912	-49
Meloxicam	Busch et al., 1998	0.60	0.35	0.855	12	13	13	22	84	8	-50
Methohexitone	Bjorkman and Redke, 2000	0.88	72.75	0.857	1000	2777	178	999	0	980	-2
Stavudine	Kaul et al., 1999	1.00	18.80	0.870	572	758	32	319	-79	466	-23
Amphotericin B	Hutchaleelaha et al., 1997; Robbie and Chiou, 1998	2.12	1.03	0.870	30	41	38	19	-57	17	-76
Fentanyl	Bjorkman and Redke, 2000	1.06	59.66	0.882	730	2525	246	743	2	384	-90
Propafenone	Puigdemont et al., 1991	0.33	71.07	0.890	1104	3117	182	2088	89	550	-101
SU 5416	Sukbuntherng et al., 2001	0.88	56.00	0.908	949	2652	179	816	-16	971	2
Ciprofloxacin	Siefert et al., 1986; Mahmood, 1999	1.10	17.65	0.927	423	1085	157	283	-50	270	-57
Valproate	Loscher, 1978; Loscher and Esenwein, 1978; Chiou and Hsu, 1988	7.04	3.66	0.944	7	202	2786	20	188	60	757
ACNU	Mitsuhashi et al., 1990	1.87	50.71	0.957	805	2950	266	423	-90	785	-3
Ethosuximide	Battino et al., 1995; Mahmood and Balian, 1996a	1.00	0.60	1.012	13	44	240	23	73	8	-63
Thiopentone	Bjorkman and Redke, 2000	0.57	3.67	1.059	215	330	53	140	-54	37	-481
AL01576	McNamara et al., 1988; Park et al., 1988; Brazzell et al., 1990	0.98	0.35	1.104	28	38	35	15	-86	30	7
Warfarin	Nagashima and Levy, 1969; von Oettingen et al., 1975	15.00	0.37	1.126	4	44	1006	2	-108	4	0
Ro25-6833	Richter et al., 1998	0.58	1.10	1.180	27	165	513	55	102	39	44
GV150526A	Iavarone et al., 1999	13.50	2.00	1.196	6	322	5266	8	28	132	2100
APE							323		78		185
S.D.							850		86		395

CI-921, 9-[[2-methoxy-4-[methylsulfonylamino]-phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide; NS-105, (+)-5-oxo-d-prolinepiperidinamide monohydrate; SU 5416, semaxanib; ACNU, 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; Ro 24-6173, an N-methyl-D-aspartate receptor antagonist; Ro25-6833, a cephalosporin; FCE22101, a penem antibiotic; DA-1131, a carbapenem antibiotic; AL01576, 2,7-difluoro-spiro-9H-fluorene-9,4'-imidazolidine)-2',5'-dione; APE, average of absolute percentage error.

$$CL = \alpha \prod P_i^{\beta_i} \quad (1)$$

and transformed into

$$\text{Log CL} = \text{Log } \alpha + \sum \beta_i \cdot \text{Log } P_i \quad (2)$$

where  $P_i$  is the variable for  $a$ ,  $b$ ,  $Rf_u$ , or  $e^{\text{ClogP}}$  (exponential values of water-octanol-water partition coefficient, ClogP). The transformed model was screened by a backward step-wise procedure ( $P$  value entrance criterion at 0.1 and  $P$  value removal criteria at 0.2) to obtain parameters of statistical significance (Intercooled Stata 7.0, Stata Corporation, College Station, TX).

## Results

The interest and rationale for developing a new allometric model equation was based on our previous findings that  $Rf_u$ , combined with ClogP, could be used to formulate rules to predict qualitatively the occurrence of large vertical allometry in predicting human CL (Tang and Mayersohn, 2005, in press). The current study was undertaken to create and test a model in which parameters such as  $Rf_u$  and ClogP, as well as coefficient  $a$  and exponent  $b$  from simple allometry, could potentially be useful to quantitatively predict human CL. ClogP was removed from the model since it did not add any statistical improvement. Coefficient  $a$ , exponent  $b$ , and  $Rf_u$  were found to be statistically significant with  $P$  values of  $<0.001$ ,  $<0.05$ , and  $<0.001$ , respectively. The model equation incorporating these three variables was:

$$CL = 36.6 \cdot (\text{ml/min}) \cdot a^{0.82} \cdot b^{0.71} \cdot Rf_u^{-0.70} (R^2 = 0.82) \quad (3)$$

The exponential value of  $b$  (0.71) is close to that of  $a$  (0.82) and  $Rf_u$  (0.70).  $b$  is relatively constant and varies over a much narrower range ( $\sim 0.35$ – $1.20$ ) than  $a$  (0.31–200) or  $Rf_u$  (0.33–20); therefore,  $b$  was not considered to be an important variable. Thus,  $a$  and  $Rf_u$  were used as the only variables to redevelop the model, which resulted in the simplified eq. 4,

$$CL = 33.35 \cdot (\text{ml/min}) \cdot a^{0.77} \cdot Rf_u^{-0.71} \quad (4)$$

which retained an  $R^2$  of 0.81, indicating that the three-variable model does not improve the prediction performance. Values for CL increase with  $a$ , indicating that the coefficient  $a$  from simple allometry is a primary determinant of CL. In contrast, CL decreases when  $Rf_u$  increases due to the negative power of  $Rf_u$ . This inverse relationship makes sense in that a higher value for  $f_u$  in animals compared with humans may lead to an over-prediction of CL by simple allometry. The inverse functional relationship between  $f_u$  and CL predicted in humans, therefore, may correct the over-predictions caused by significant differences in  $f_u$  between animals and humans.

The exponents of  $a$  and  $Rf_u$  have very similar absolute values. Changing  $-0.71$  to  $-0.77$  for the exponent of the  $f_u$  ratio only slightly affects CL. For example, an  $Rf_u$  of 10 raised to the power  $-0.71$  is 0.19, whereas 10 raised to the power  $-0.77$  is 0.17. Most  $f_u$  ratios are smaller than 10; therefore, the equation was further simplified to

$$CL = 33.35 \cdot (\text{ml/min}) \cdot \left( \frac{a}{Rf_u} \right)^{0.77} \quad (5)$$

The term,  $a/Rf_u$ , could be referred as an “ $f_u$ -corrected  $a$ .” The predictability of CL estimations for eq. 5, as well as for simple allometry and ROE, are given in Table 1. The significant improvement in prediction performance by the proposed model, compared with ROE, could be judged from three perspectives.

First, the average absolute values of percentage error by eq. 5, ROE, and simple allometry were 78%, 185%, and 323%, respectively. The significant improvement in prediction by the new model is apparent.

TABLE 2

A summary of outliers for predictions of human clearance (PEs greater than 200%) based on simple allometry, new model equation, and rule of exponents

Methods	APE	N (PE > 200%)	N (PE > 500%)	N (PE > 1000%)
	%			
Simple allometry	323	11	6	5
Rule of exponents	185	11	6	3
Equation 5	78	6	1	0

APE, average of absolute percentage error.

Second, using the new model (e.g., eq. 5), only six compounds had percentage errors over 200%, with 548% for diazepam and 200 to 300% for the other five. In contrast, 11 compounds using the ROE method had prediction percentage errors greater than 200%, with 2100% for GV150526A, 1626% for diazepam, 1485% for tamsulosin, and 200 to 1000% for the other eight compounds (Table 2). Therefore, the new model predicted the large vertical allometry with greater success compared with ROE.

Comparisons of the predictability of human CL from simple allometry with the new model (eq. 5) and ROE may be visualized in Fig. 1




FIG. 1. Predicted human clearance as a function of observed human clearance. Predicted values are based upon simple allometry (top), the new model equation derived here (eq. 5; middle) and the rule of exponents (bottom). The solid lines are the lines of identity and the dashed lines represent a range associated with 200% error.




FIG. 2. Percentage error in prediction of human clearance as a function of observed human clearance. Percentage errors are from predictions based upon simple allometry (top), the new model eq. 5 (middle), and the rule of exponents (bottom). The inset plots are limited to 400% error, which encompasses most of the error range. The solid lines indicate 0% error. The dashed lines indicate the range associated with 200% error. Symbols: simple allometric slope values less than 0.7 (circle), less than 0.7–1.0 (triangle), or greater than 1.0 (rectangle).

and Fig. 2. The dashed line in the graphs represents a 200% error range. Simple allometry results in substantial over-prediction of human CL for many compounds (especially those with low CL). The ROE method considerably reduces that error, whereas it still retains a few large over-predictions and leads to biased under-predictions. The under-predictions by the ROE method are primarily the result of applying MLP or BrW corrections to compounds having allometric




FIG. 3. Unbound fraction of drug in plasma ( $f_u$ ) for the average in all animal species (top) and in humans (bottom) as a function of  $f_u$  in rats for 61 compounds. The average  $f_u$  values in animals are based on at least two animal species including rats. The solid lines indicate the lines of 5-fold or 0.2-fold. The dotted lines indicate the lines of 2-fold or 0.5-fold. The dashed lines indicate the lines of identity.

exponents greater than 0.70. In contrast, the new model equation proposed here results in more accurate predictions of human CL and a more random pattern of errors.

### Discussion

The use of  $f_u$  ratio between rats and humans, rather than between all animals and humans, was based on our observation that the  $f_u$  in rats is representative of the average  $f_u$  in animals (Fig.3). In contrast, many significant differences between  $f_u$  in rats and  $f_u$  in humans were observed (Fig. 3). One question could be raised concerning why scaling by the unbound CL approach did not provide stable and good predictability, because it appears that correcting CL by  $f_u$  in each animal species would be more favorable than just considering only rats and humans. One possible explanation could be attributed to the serious error underlying data fitting to the power function (Smith, 1984) and the considerable measurement error of  $f_u$ , especially for highly plasma-bound compounds. When three or more animal species are included for scaling unbound CL, the same number of  $f_u$  variables with errors is also introduced into the data fitting, and may generate



greater error in predicting human values than what is generated from the error noted in only one species, the rat, in the new proposed model. Here is an example to visualize this concept. Suppose three species, mouse (0.03 kg), rat (0.25 kg), and dog (15 kg), are used for allometric scaling of unbound CL. The final predicted CL in humans by allometry can be expressed as:

$$CL_{\text{predicted}} = A \cdot (f_u^{\text{mouse}})^{0.36} \cdot (f_u^{\text{rat}})^{-0.17} \cdot (f_u^{\text{dog}})^{-1.19} \cdot (f_u^{\text{human}})^{1.0} \quad (6)$$

where  $A$  is a function of CL observed in each animal species and the body weight of animals (derivation under *Appendix*). The new model can be expressed as:

$$CL_{\text{predicted}} = B \cdot (f_u^{\text{rat}})^{-0.77} \cdot (f_u^{\text{human}})^{0.77} \quad (7)$$

where  $B$  is not equal to  $A$ , but is also a function of CL observed in each animal species and the body weight of animals. It is obvious that the correction of  $f_u$  in each species incorporates more variance by introducing more  $f_u$  variables compared with both simple allometry and the new model.

Certainly, the new model is empirical, just as are all of the other approaches. No solid physiological or biochemical basis could be offered at this time. The model proposed here does not consider many other potential types of useful information such as in vitro metabolic differences across species, which may account for deviations in predictions. Therefore, the empirical model that has been proposed should be expected, in practice, to result in errors in prediction, such as when a significant metabolic/elimination difference is seen across the species examined. Nevertheless, the new model was shown to be simple, reasonable, and more predictive than the currently available approaches. In particular, the new model significantly improves for the first time the prediction of the occurrence of large vertical allometry noted in humans.

In summary, a novel and simple model, incorporating  $a$  and the  $f_u$  ratio between rats and humans, has been proposed and shown to provide a better predictability than the currently available allometric techniques in estimating values of CL in humans. Most important, it significantly improves the prediction of large vertical allometry.<sup>2</sup>

**Acknowledgments.** We thank Dr. Harold Boxenbaum for useful suggestions in the development of the new model equations, and Drs. Stacey Tannenbaum (Novartis Pharmaceutical Co.) and Iftekkar Mahmood (U.S. Food and Drug Administration) for providing part of the allometric data used in the analyses.

## Appendix: Derivation of Equation 5

### Part I: Derivation of the Function Relating Predicted PK Parameters in Humans ( $P_{\text{predicted}}$ ) to Animal Body Weights ( $W$ ) and Observed Animal PK Parameters ( $P_i$ )

The log-log transformation of  $P = a \cdot W^b$  gives

$$\log P = \log a + b \cdot \log W \quad (A1)$$

<sup>2</sup> The proposed model (eq. 5) was tested using one example of large vertical allometry (reboxetine), whose data were available to the authors during the revision of the manuscript. We predicted an  $Rf_u$  greater than 5 for reboxetine. The data kindly provided by one of the reviewers (courtesy of Pfizer, Inc.) showed  $f_u$  values of 0.17 and 0.02 in rats and humans, respectively, which translate to an  $Rf_u$  of 8.5. Prediction of human CL based upon eq. 5 resulted in a PE of 104%, compared with 1395% and 804% based upon simple allometry and the ROE method, respectively.

Let

$$Y = \log P; X = \log W; a = 10^\alpha; b = \beta$$

Then, eq. A1 can be simplified to

$$Y = \alpha + \beta \cdot X \quad (A2)$$

Suppose  $n$  different animal species are used for allometric scaling. Therefore, there are  $n$  sets of  $(X, Y)$  data to fit using linear regression. Based on the method of least squares for linear regression,  $\alpha$  and  $\beta$  can be calculated as

$$\beta = \frac{\sum_{i=1}^n (X_i - \bar{X})(Y_i - \bar{Y})}{\sum_{i=1}^n (X_i - \bar{X})^2} \quad (A3)$$

$$\alpha = \bar{Y} - \beta \cdot \bar{X} \quad (A4)$$

Substituting  $Y = \log P$ ,  $X = \log W$  into eqs. A3 and A4, and further substituting  $\alpha$  and  $\beta$  into  $a = 10^\alpha$ ,  $b = \beta$ , expressions of  $a$  and  $b$  are obtained as

$$a = \prod_{i=1}^n P_i^{A_i} \quad (A5)$$

$$b = \sum_{i=1}^n B_i \cdot \log P_i \quad (A6)$$

where

$$A_i = \frac{1}{n} \left( 1 - B_i \cdot \log \prod_{j=1}^n W_j \right) \quad (A7)$$

$$B_i = \frac{1}{n} \cdot \frac{\log \frac{W_i^{n-1}}{\prod_{k=1, k \neq i}^n W_k}}{\left( \sum_{k=1}^n \left( \log W_k - \frac{\log \prod_{l=1}^n W_l}{n} \right)^2 \right)} \quad (A8)$$

By assuming a human body weight of 70 kg, the predicted  $P$  in humans is obtained from

$$P_{\text{predicted}} = a \cdot 70^b = \prod_{i=1}^n P_i^{(A_i + 1.845B_i)} \quad (A9)$$

where  $P_{\text{predicted}}$  is the predicted PK parameter in humans and  $P_i$  is the measured PK parameter in an animal species,

$$A_i = \frac{1}{n} \left( 1 - B_i \cdot \log \prod_{j=1}^n W_j \right) \quad (A10)$$

$$B_i = \frac{1}{n} \cdot \frac{\log \frac{W_i^{n-1}}{\prod_{k=1, k \neq i}^n W_k}}{\left( \sum_{k=1}^n \log W_k - \frac{\log \prod_{l=1}^n W_l}{n} \right)^2} \quad (\text{A11})$$

where  $W$  is the animal body weight.

## Part II: Derivation of Equation 5 Based on Equation A9

Based on eq. A9, predicted human CL ( $CL_{\text{predicted}}$ ) using simple allometry from a combination of animals such as the mouse (0.03 kg), rat (0.25 kg), and dog (15 kg) gives

$$CL_{\text{predicted}} = (CL^{\text{mouse}})^{-0.36} \cdot (CL^{\text{rat}})^{0.17} \cdot (CL^{\text{dog}})^{1.19} \quad (\text{A12})$$

Since

$$CL_u = \frac{CL}{f_u} \quad (\text{A13})$$

scaling of unbound CL can be done by substituting  $CL_u$  for CL, resulting in

$$\left( \frac{CL_{\text{predicted}}}{f_u^{\text{human}}} \right)^{1.0} = \left( \frac{CL^{\text{mouse}}}{f_u^{\text{mouse}}} \right)^{-0.36} \cdot \left( \frac{CL^{\text{rat}}}{f_u^{\text{rat}}} \right)^{0.17} \cdot \left( \frac{CL^{\text{dog}}}{f_u^{\text{dog}}} \right)^{1.19} \quad (\text{A14})$$

Therefore, CL predicted in humans by scaling unbound CL can be obtained,

$$CL_{\text{predicted}} = A \cdot (f_u^{\text{mouse}})^{0.36} \cdot (f_u^{\text{rat}})^{-0.17} \cdot (f_u^{\text{dog}})^{-1.19} \cdot (f_u^{\text{human}})^{1.0} \quad (\text{A15})$$

where  $A$  is the CL value predicted in humans using simple allometry and is equal to

$$A = (CL^{\text{mouse}})^{-0.36} \cdot (CL^{\text{rat}})^{0.17} \cdot (CL^{\text{dog}})^{1.19} \quad (\text{A16})$$

By substituting  $a$  from eq. A5, the new model equation (eq. 5 in text) is

$$CL = 33.35 \cdot (\text{ml/min}) \cdot \left( \frac{a}{Rf_u} \right)^{0.77} \quad (\text{A17})$$

and can be expressed as

$$CL = 33.35 \cdot (\text{ml/min}) \cdot \left( \prod_{i=1}^n P_i^{A_i} \right)^{0.77} \cdot \left( \frac{f_u^{\text{human}}}{f_u^{\text{rat}}} \right)^{0.77} \quad (\text{A18})$$

That is,

$$CL_{\text{predicted}} = B \cdot (f_u^{\text{rat}})^{-0.77} \cdot (f_u^{\text{human}})^{0.77} \quad (\text{A19})$$

where

$$B = 33.35 \cdot (\text{ml/min}) \cdot \left( \prod_{i=1}^n P_i^{A_i} \right)^{0.77} \quad (\text{A20})$$

## References

Adusumalli VE, Yang JT, Wong KK, Kucharczyk N, and Sofia RD (1991) Felbamate pharmacokinetics in the rat, rabbit and dog. *Drug Metab Dispos* **19**:1116–1125.  
 Battino D, Estienne M, and Avanzini G (1995) Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide, and mesuximide. *Clin Pharmacokinet* **29**:257–286.

Belpaire FM, Bogaert MG, and Mussche MM (1977) Influence of acute renal failure on the protein binding of drugs in animals and in man. *Eur J Clin Pharmacol* **11**:27–32.  
 Bjorkman S and Redke F (2000) Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man. *J Pharm Pharmacol* **52**:1065–1074.  
 Bombardt PA, Brewer JE, and Johnson MG (1994) Protein binding of tilirilazad (U-74006) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum. *J Pharmacol Exp Ther* **269**:145–150.  
 Bonati M, Latini R, Tognoni G, Young JF, and Garattini S (1984) Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. *Drug Metab Rev* **15**:1355–1383.  
 Boxenbaum H (1982) Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. *J Pharmacokinet Biopharm* **10**:201–227.  
 Boxenbaum H and Fertig JB (1984) Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. *Eur J Drug Metab Pharmacokinet* **9**:177–183.  
 Brazzell RK, Park YH, Wooldridge CB, McCue B, Barker R, Couch R, and York B (1990) Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. *Drug Metab Dispos* **18**:435–440.  
 Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C, and Roth W (1998) Pharmacokinetics of meloxicam in animals and the relevance to humans. *Drug Metab Dispos* **26**:576–584.  
 Chiou WL and Hsu FH (1988) Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. *Pharm Res (NY)* **5**:668–672.  
 Cosson VF, Fuseau E, Efthymiopoulos C, and Bye A (1997) Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I. interspecies allometric scaling. *J Pharmacokinet Biopharm* **25**:149–167.  
 Efthymiopoulos C, Battaglia R, and Strolin BM (1991) Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. *J Antimicrob Chemother* **27**:517–526.  
 Feng MR, Lou X, Brown RR, and Hutchaleelaha A (2000) Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. *Pharm Res (NY)* **17**:410–418.  
 Gaspari F and Bonati M (1990) Interspecies metabolism and pharmacokinetic scaling of theophylline disposition. *Drug Metab Rev* **22**:179–207.  
 Higuchi S, Sasaki H, and Seki T (1980) Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs and humans. *Xenobiotica* **10**:897–903.  
 Hinderling PH, Dilea C, Koziol T, and Millington G (1993) Comparative kinetics of sematilide in four species. *Drug Metab Dispos* **21**:662–669.  
 Hutchaleelaha A, Chow HH, and Mayersohn M (1997) Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. *J Pharm Pharmacol* **49**:178–183.  
 Iavarone L, Hoke JF, Bottacini M, Barnaby R, and Preston GC (1999) First time in human for GV196771: interspecies scaling applied on dose selection. *J Clin Pharmacol* **39**:560–566.  
 Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. *J Pharmacol Exp Ther* **277**:1630–1641.  
 Izumi T, Hoshiyama K, Enomoto S, Sasahara K, and Sugiyama Y (1997) Determination of protein binding of troglitazone stereoisomers by fluorometric titration. *Biopharm Drug Dispos* **18**:241–257.  
 Kaul S, Dandekar KA, Schilling BE, and Barbhuiya RH (1999) Toxicokinetics of 2',3'-dihydro-3'-deoxythymidine, stavudine (D4T). *Drug Metab Dispos* **27**:1–12.  
 Kawakami J, Yamamoto K, Sawada Y, and Iga T (1994) Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. *J Pharmacokinet Biopharm* **22**:207–227.  
 Kim SH, Kim WB, and Lee MG (1998a) Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs and prediction of human pharmacokinetics. *Biopharm Drug Dispos* **19**:231–235.  
 Kim SH, Kwon JW, and Lee MG (1998b) Pharmacokinetics and tissue distribution of a new carbapenem DA-1131, after intravenous administration to mice, rats, rabbits and dogs. *Biopharm Drug Dispos* **19**:219–229.  
 Komiya M, Kikuchi Y, Tachibana A, and Yano K (1981) Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. *Antimicrob Agents Chemother* **20**:176–183.  
 Kumagai Y, Yokota S, Isawa S, Murasaki M, Mukai H, and Miyatake S (1999) Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects. *Int J Clin Pharmacol Res* **19**:1–8.  
 Lave T, Coassolo P, Ubeaud G, Brandt R, Schmitt C, Dupin S, Jaeck D, and Chou RC (1996a) Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. *Pharm Res (NY)* **13**:97–101.  
 Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, and Coassolo P (1997) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. *J Pharm Sci* **86**:584–590.  
 Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, and Coassolo P (1996b) Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. *Xenobiotica* **26**:839–851.  
 Lazniecek M, Lamka J, and Kvetina J (1982) On the interaction of diazepam with human, rat and mouse plasma proteins and erythrocytes. *Biochem Pharmacol* **31**:1455–1458.  
 Lee FH, Pfeffer M, Van Harken DR, Smyth RD, and Hottendorf GH (1980) Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. *Antimicrob Agents Chemother* **17**:188–192.  
 Leusch A, Troger W, Greischel A, and Roth W (2000) Pharmacokinetics of the M1-agonist talsacilidine in mouse, rat, rabbit and monkey and extrapolation to man. *Xenobiotica* **30**:797–813.  
 Lin JH, Chiba M, Balani SK, Chen IW, Kwei GY, Vastag KJ, and Nishime JA (1996) Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. *Drug Metab Dispos* **24**:1111–1120.  
 Loscher W (1978) Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. *J Pharmacol Exp Ther* **204**:255–261.

- Loscher W and Esenwein H (1978) Pharmacokinetics of sodium valproate in dog and mouse. *Arzneim-Forsch* **28**:782–787.
- Mahmood I (1999) Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. *J Pharm Pharmacol* **51**:905–910.
- Mahmood I (2000) Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. *J Clin Pharmacol* **40**:1439–1446.
- Mahmood I (2002) Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. *Drug Metab Drug Interact* **19**:49–64.
- Mahmood I (2005) Commentary: the correction factors do help in improving the prediction of human clearance from animal data. *J Pharm Sci* **94**:940–944.
- Mahmood I and Balian JD (1996a) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. *Xenobiotica* **26**:887–895.
- Mahmood I and Balian JD (1996b) Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. *J Pharm Sci* **85**:411–414.
- Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, and Tsunoo M (1998) Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs and humans. *Drug Metab Dispos* **26**:240–245.
- Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M, and Kawaguchi Y (1990) Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. *J Pharmacobiodyn* **13**:602–611.
- McNamara PJ, Blouin RA, and Brazzell RK (1988) The protein binding of phenytoin, propranolol, diazepam and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. *Pharm Res (NY)* **5**:261–265.
- Mitsushashi Y, Sugiyama Y, Ozawa S, Nitani T, Sasahara K, Nakamura K, Tanaka M, Nishimura T, Inaba M, and Kobayashi T (1990) Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up. *Cancer Chemother Pharmacol* **27**:20–26.
- Mukai H, Sugimoto T, Ago M, and Morino A (1999) Pharmacokinetics of NS-105, a novel cognition enhancer. 1st Communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105. *Arzneim-Forsch* **49**:881–890.
- Murakawa T, Sakamoto H, Fukada S, Nakamoto S, Hirose T, Itoh N, and Nishida M (1980) Pharmacokinetics of ceftizoxime in animals after parenteral dosing. *Antimicrob Agents Chemother* **17**:157–164.
- Nagashima R and Levy G (1969) Comparative pharmacokinetics of coumarin anticoagulants. V. Kinetics of warfarin elimination in the rat, dog and rhesus monkey compared to man. *J Pharm Sci* **58**:845–849.
- Nagilla R and Ward K (2004) A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog and monkey to humans. *J Pharm Sci* **93**:2522–2534.
- Nagilla R and Ward K (2005) Correspondence to Commentary: "A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog and monkey to humans." *J Pharm Sci* **93**:946–947.
- Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, and Shimizu M (1983) Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs and monkeys. *Antimicrob Agents Chemother* **24**:54–60.
- Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. *Drug Metab Dispos* **29**:1316–1324.
- Ohshima T, Hasegawa T, John I, and Kitazawa S (1991) Protein binding of cefpiramide in the plasma of various species. *J Pharm Pharmacol* **43**:805–806.
- Okazaki O, Kurata T, Hakusui H, and Tachizawa H (1992) Species-related stereoselective disposition of ofloxacin in the rat, dog and monkey. *Xenobiotica* **22**:439–450.
- Palmer KJ and McTavish D (1993) Felbamate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in epilepsy. *Drugs* **45**:1041–1065.
- Park YH, Wooldridge CB, Mattern J, Stoltz ML, and Brazzell RK (1988) Disposition of the aldose reductase inhibitor AL01576 in rats. *J Pharm Sci* **77**:110–115.
- Paxton JW, Kim SN, and Whitfield LR (1990) Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs and humans. *Cancer Res* **50**:2692–2697.
- Puigdemont A, Guitart R, de Mora F, and Arboix M (1991) Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other animal species. *J Pharm Sci* **80**:1106–1109.
- Richter WF, Heizmann P, Meyer J, Starke V, and Lave T (1998) Animal pharmacokinetics and interspecies scaling of Ro 25–6833 and related (lactamylvinyl)cephalosporins. *J Pharm Sci* **87**:496–500.
- Robbie G and Chiou WL (1998) Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. *Pharm Res (NY)* **15**:1630–1636.
- Sanwald-Ducray P and Dow J (1997) Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. *Xenobiotica* **27**:189–201.
- Sawada Y, Hanano M, Sugiyama Y, and Iga T (1984) Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. *J Pharmacokinetic Biopharm* **12**:241–261.
- Scatina JA, Kimmel HB, Weinstein V, Troy SM, Sisenwine SF, and Cayen MN (1990) Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug. *Biopharm Drug Dispos* **11**:445–461.
- Siefert HM, Domdey-Bette A, Henninger K, Huckle F, Kohlsdorfer C, and Stass HH (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. *J Antimicrob Chemother* **43** (Suppl B):69–76.
- Siefert HM, Maruhn D, Maul W, Forster D, and Ritter W (1986) Pharmacokinetics of ciprofloxacin. 1st Communication: Absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. *Arzneim-Forsch* **36**:1496–1502.
- Smith DA, Rasmussen HS, Stopher DA, and Walker DK (1992) Pharmacokinetics and metabolism of dofenilide in mouse, rat, dog and man. *Xenobiotica* **22**:709–719.
- Smith RJ (1984) Allometric scaling in comparative biology: problems of concept and method. *Am J Physiol* **246**:R152–R160.
- Stopher DA, Beresford AP, Macrae PV, and Humphrey MJ (1988) The metabolism and pharmacokinetics of amlodipine in humans and animals. *J Cardiovasc Pharmacol* **12** (Suppl 7):S55–S59.
- Sukbunthorn J, Cropp G, Hannah A, Wagner GS, Shawver LK, and Antonian L (2001) Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. *J Pharm Pharmacol* **53**:1629–1636.
- Tang H and Mayersohn M (2005) A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. *J Pharm Sci*, in press.
- Terakawa M, Tokuma Y, Shishido A, and Noguchi H (1987) Pharmacokinetics of nilvadipine in healthy volunteers. *J Clin Pharmacol* **27**:111–117.
- Tokuma Y, Fujiwara T, and Noguchi H (1987) Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. *Xenobiotica* **17**:1341–1349.
- Tsunekawa Y, Hasegawa T, Nadai M, Takagi K, and Nabeshima T (1992) Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. *J Pharm Pharmacol* **44**:594–599.
- Ubeaud G, Schmitt C, Jaeck D, Lave T, and Coassolo P (1995) Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. *Xenobiotica* **25**:1381–1390.
- van Hoogdalem EJ, Soeishi Y, Matsushima H, and Higuchi S (1997) Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. *J Pharm Sci* **86**:1156–1161.
- von Oettingen U, Niedner R, and Meyer F (1975) [Rodenticidal action of warfarin/4th communication: Binding to serum albumin of mice and rats (author's transl)]. *Arzneim-Forsch* **25**:1705–1706.
- Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, and Wright PA (1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. *Xenobiotica* **29**:297–310.
- Widman M, Nilsson LB, Bryske B, and Lundstrom J (1993) Disposition of remoxipride in different species. Species differences in metabolism. *Arzneim-Forsch* **43**:287–297.

---

**Address correspondence to:** Michael Mayersohn, College of Pharmacy, The University of Arizona, 1703 East Mabel Street, Tucson, AZ 85721. E-mail: mayersohn@pharmacy.arizona.edu

---